Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M148,056Revenue $M14,745Net Margin (%)33.7Altman Z-Score17.7
Enterprise Value $M147,099EPS $1.9Operating Margin %45.5Piotroski F-Score8
P/E(ttm)25.7Beneish M-Score-2.9Pre-tax Margin (%)42.0Higher ROA y-yY
Price/Book19.610-y EBITDA Growth Rate %18.8Quick Ratio1.0Cash flow > EarningsY
Price/Sales10.85-y EBITDA Growth Rate %19.6Current Ratio1.3Lower Leverage y-yY
Price/Free Cash Flow27.7y-y EBITDA Growth Rate %41.1ROA % (ttm)33.9Higher Current Ratio y-yN
Dividend Yield %1.5PEG1.3ROE % (ttm)69.1Less Shares Outstanding y-yY
Payout Ratio %39.0Shares Outstanding M2,650ROIC % (ttm)111Gross Margin Increase y-yY

Gurus Latest Trades with NVO

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
NVOKen Fisher 2015-12-31 Reduce-0.02%$52.93 - $58.77
($55.36)
$ 48.90-12%Reduce -1.76%11,447,413
NVOMario Gabelli 2015-12-31 Add$52.93 - $58.77
($55.38)
$ 48.90-12%Add 0.65%6,210
NVOKen Fisher 2015-09-30 Reduce-0.07%$52.8 - $60.23
($56.62)
$ 48.90-14%Reduce -5.23%11,652,268
NVORuane Cunniff 2015-09-30 Reduce$52.8 - $60.23
($56.62)
$ 48.90-14%Reduce -0.59%81,320
NVOMario Gabelli 2015-09-30 Reduce$52.8 - $60.23
($56.62)
$ 48.90-14%Reduce -5.73%6,170
NVOKen Fisher 2015-06-30 Reduce-0.04%$53.39 - $58.02
($56.17)
$ 48.90-13%Reduce -2.88%12,295,864
NVORuane Cunniff 2015-06-30 Reduce$53.39 - $58.02
($56.17)
$ 48.90-13%Reduce -0.30%81,800
NVOMario Gabelli 2015-06-30 Reduce$53.39 - $58.02
($56.17)
$ 48.90-13%Reduce -2.31%6,545
NVOKen Fisher 2015-03-31 Reduce-0.03%$41.9 - $54.68
($46.05)
$ 48.906%Reduce -2.91%12,660,235
NVOMario Gabelli 2015-03-31 Reduce$41.9 - $54.68
($46.05)
$ 48.906%Reduce -0.30%6,700
NVORuane Cunniff 2015-03-31 Reduce$41.9 - $54.68
($46.05)
$ 48.906%Reduce -0.17%82,050
NVORuane Cunniff 2014-09-30 Reduce-0.02%$43.9 - $49.03
($46)
$ 48.906%Reduce -52.87%75,642
NVORuane Cunniff 2014-06-30 Reduce-0.02%$42.28 - $46.52
($44.12)
$ 48.9011%Reduce -33.85%160,492
NVORuane Cunniff 2014-03-31 Reduce-0.01%$36.722 - $48.23
($42.37)
$ 48.9015%Reduce -21.98%242,630
NVORuane Cunniff 2013-12-31 Add0.02%$32.72 - $36.95
($34.87)
$ 48.9040%Add 58.71%310,970
NVOTom Gayner 2013-12-31 Reduce$32.72 - $36.95
($34.87)
$ 48.9040%Reduce -0.23%1,106,000
NVOKen Fisher 2013-12-31 Add$32.72 - $36.95
($34.87)
$ 48.9040%Add 0.29%13,553,935
NVOTom Gayner 2013-09-30 Reduce-0.02%$31.67 - $35.24
($33.64)
$ 48.9045%Reduce -1.51%1,108,500
NVOMario Gabelli 2013-09-30 Reduce$31.67 - $35.24
($33.64)
$ 48.9045%Reduce -0.58%8,520
NVORuane Cunniff 2013-09-30 Add$31.67 - $35.24
($33.64)
$ 48.9045%Add 13.12%195,930
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

NVO is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


NVO: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Quarterly/Annual Reports about NVO:

    News about NVO:

    Articles On GuruFocus.com
    Jim Simons' Top Holdings Include VeriSign, Chipotle Dec 15 2015 
    Value Investing in BioPharma Nov 18 2015 
    Jim Simons' Five Most-Heavily Weighted Holdings Oct 21 2015 
    Ken Fisher Reduces Stake in Toyota, Increases Position in Anheuser-Busch Oct 20 2015 
    Jim Simons and Ken Fisher Decrease Exposure on Novo Nordisk A/S Sep 14 2015 
    Nintai Returns: Q2 2015 Jul 01 2015 
    Leith Wheeler Investment Funds First Quarter 2015 Review Jun 15 2015 
    Jim Simons' Top 3 Positions and One That Doubled Return Jun 10 2015 
    Weekly 52-Week Highs Highlight: ALTR, AIG, LUX, NVO, EXPE May 03 2015 
    MannKind Looks Good For Long Term Investors Apr 29 2015 

    More From Other Websites
    Novo Nordisk A/S Earnings Analysis: 2015 By the Numbers Feb 05 2016
    Novo Nordisk Posts In Line Q4 Earnings, Tops Revenues Feb 04 2016
    [$$] Novo Nordisk lowers earnings targets as drug price pressure grows Feb 03 2016
    Novo Nordisk CEO Sees Limited Scope for U.S. Price Increases Feb 03 2016
    [$$] Novo Nordisk Shares Plunge on Profit Growth Forecast Feb 03 2016
    Drugmaker Novo surprises with long-term profit target cut Feb 03 2016
    Novo Nordisk CEO: Optimism on Increased U.S. Access Feb 03 2016
    More Losses for Europe Stocks as Banks Fall, Earnings Disappoint Feb 03 2016
    Novo Nordisk Quarterly Profit Misses Estimates on Victoza Feb 03 2016
    China’s diabetes boom promises $23 billion pot for drug makers Jan 30 2016
    Tresiba® demonstrates significantly lower rate of hypoglycaemia than insulin glargine in blinded... Jan 29 2016
    How Recent Events Could Affect Novo Nordisk’s Earnings Jan 26 2016
    Novo Nordisk A/S - aktietilbagekøbsprogram Jan 25 2016
    Novo Nordisk A/S - Share repurchase programme Jan 25 2016
    How Is Novo Nordisk’s Position in the Diabetes Segment? Jan 18 2016
    What to Expect from Novo Nordisk’s 4Q15 Earnings Jan 18 2016
    Novo Nordisk A/S - Aktietilbagekøbsprogram Jan 18 2016
    Novo Nordisk A/S - Share repurchase programme Jan 18 2016

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.

    User Comments

    Gintaras58
    ReplyGintaras58 - 1 year ago
    few excellent prducts to come soon
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    FEEDBACK